Synopsis

Source of validity: Scientific
Rating (out of 5): 2

Boswellic Acid and Fibrosis: Scientific Evidence

Boswellic acids are bioactive compounds derived from the resin of Boswellia species (frankincense). They have been studied for their anti-inflammatory and anti-fibrotic properties in preclinical research. In several in vitro and animal studies, boswellic acids have shown potential to inhibit key pathways involved in fibrosis, such as the transforming growth factor-beta (TGF-β) signaling pathway and the activity of pro-fibrotic cytokines. These effects have been observed in models of lung, liver, and kidney fibrosis.

For example, a 2011 study in rats demonstrated that boswellic acid administration reduced markers of liver fibrosis and inflammation. Other experiments have shown attenuation of lung fibrosis in animal models, attributed to the suppression of fibroblast proliferation and collagen deposition. The proposed mechanisms include inhibition of 5-lipoxygenase, reduction of oxidative stress, and modulation of immune cell activity.

However, there is a lack of robust clinical trials in humans specifically addressing boswellic acid's effectiveness in treating established fibrotic diseases. Most evidence is limited to laboratory and animal research, and while promising, it cannot be directly extrapolated to human patients at this stage. Therefore, while there is some scientific basis for the use of boswellic acid in fibrosis, the current evidence is preliminary and limited, justifying a moderate evidence rating.

More about Boswellic Acid
More about Fibrosis

Other ingredients used for Fibrosis

Other health conditions supported by Boswellic Acid

Products containing Boswellic Acid